CEN Biotech Statistics
Total Valuation
CEN Biotech has a market cap or net worth of 6,526.
| Market Cap | 6,526 |
| Enterprise Value | n/a |
Important Dates
The next estimated earnings date is Thursday, August 14, 2025.
| Earnings Date | Aug 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CEN Biotech has 65.26 million shares outstanding.
| Current Share Class | 65.26M |
| Shares Outstanding | 65.26M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +4.32% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.01 |
| PB Ratio | -0.00 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.03
| Current Ratio | 0.03 |
| Quick Ratio | 0.02 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -9.44 |
| Interest Coverage | -3.74 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -10.10% |
| Return on Invested Capital (ROIC) | -22.70% |
| Return on Capital Employed (ROCE) | 68.77% |
| Revenue Per Employee | 258,259 |
| Profits Per Employee | -773,965 |
| Employee Count | 4 |
| Asset Turnover | 0.13 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -50.00% in the last 52 weeks. The beta is -78.92, so CEN Biotech's price volatility has been lower than the market average.
| Beta (5Y) | -78.92 |
| 52-Week Price Change | -50.00% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 30.67 |
| Average Volume (20 Days) | 469 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.04 |
Income Statement
In the last 12 months, CEN Biotech had revenue of 1.03 million and -3.10 million in losses. Loss per share was -0.05.
| Revenue | 1.03M |
| Gross Profit | 1.03M |
| Operating Income | -1.32M |
| Pretax Income | -3.13M |
| Net Income | -3.10M |
| EBITDA | -889,849 |
| EBIT | -1.32M |
| Loss Per Share | -0.05 |
Balance Sheet
The company has 148,151 in cash and 5.62 million in debt, giving a net cash position of -5.47 million or -0.08 per share.
| Cash & Cash Equivalents | 148,151 |
| Total Debt | 5.62M |
| Net Cash | -5.47M |
| Net Cash Per Share | -0.08 |
| Equity (Book Value) | -2.11M |
| Book Value Per Share | -0.03 |
| Working Capital | -9.53M |
Cash Flow
In the last 12 months, operating cash flow was -590,725 and capital expenditures -4,225, giving a free cash flow of -594,950.
| Operating Cash Flow | -590,725 |
| Capital Expenditures | -4,225 |
| Free Cash Flow | -594,950 |
| FCF Per Share | -0.01 |
Margins
Gross margin is 100.00%, with operating and profit margins of -127.54% and -299.69%.
| Gross Margin | 100.00% |
| Operating Margin | -127.54% |
| Pretax Margin | -303.21% |
| Profit Margin | -299.69% |
| EBITDA Margin | -86.14% |
| EBIT Margin | -127.54% |
| FCF Margin | n/a |
Dividends & Yields
CEN Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -48.69% |
| Shareholder Yield | n/a |
| Earnings Yield | -47,438.88% |
| FCF Yield | -9,116.61% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CEN Biotech has an Altman Z-Score of -9.66. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -9.66 |
| Piotroski F-Score | n/a |